Preferences and acceptability for long‐acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya

Long‐acting pre‐exposure prophylaxis (PrEP) options could overcome barriers to oral PrEP persistence during pregnancy and postpartum. We evaluated long‐acting PrEP preferences among oral PrEP‐experienced pregnant and postpartum women in South Africa and Kenya, countries with high PrEP coverage with pending regulatory approvals for long‐acting injectable cabotegravir and the dapivirine vaginal ring (approved in South Africa, under review in Kenya).

[1]  L. Myer,et al.  Adherence challenges with daily oral pre‐exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study , 2022, Journal of the International AIDS Society.

[2]  S. Delany-Moretlwe,et al.  Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial , 2022, AIDS and Behavior.

[3]  S. Delany-Moretlwe,et al.  Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial , 2022, The Lancet.

[4]  L. Myer,et al.  Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Pregnant and Post-partum Women from Cape Town, South Africa , 2022, AIDS and Behavior.

[5]  T. Exner,et al.  Women’s Perceptions of HIV- and Sexuality-Related Stigma in Relation to PrEP: Qualitative Findings from the Masibambane Study, Durban, South Africa , 2022, AIDS and Behavior.

[6]  L. Myer,et al.  Early pre‐exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa , 2022, Journal of the International AIDS Society.

[7]  A. van der Straten,et al.  Sexual Attitudes, Beliefs, Practices, and HIV Risk During Pregnancy and Post-delivery: A Qualitative Study in Malawi, South Africa, Uganda, and Zimbabwe , 2021, AIDS and Behavior.

[8]  J. Polli,et al.  885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials , 2021, HIV medicine.

[9]  Gabrielle E. O'Malley,et al.  Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya , 2021, PloS one.

[10]  A. Puren,et al.  Recent HIV infection among pregnant women in the 2017 antenatal sentinel cross–sectional survey, South Africa: Assay–based incidence measurement , 2021, PloS one.

[11]  Ashley J. Mayo,et al.  Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial , 2021, AIDS and Behavior.

[12]  Ashley J. Mayo,et al.  Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. , 2021, The lancet. HIV.

[13]  A. van der Straten,et al.  Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa , 2021, Sexual and reproductive health matters.

[14]  Gabrielle E. O'Malley,et al.  Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. , 2020, Journal of acquired immune deficiency syndromes.

[15]  L. Myer,et al.  Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation, Retention and Adherence , 2020, AIDS and Behavior.

[16]  J. Baeten,et al.  Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial , 2020, AIDS and Behavior.

[17]  B. Chi,et al.  Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. , 2020, The lancet. HIV.

[18]  J. Baeten,et al.  Community Perceptions About Use of Pre-exposure Prophylaxis Among Adolescent Girls and Young Women in Kenya. , 2020, The Journal of the Association of Nurses in AIDS Care : JANAC.

[19]  M. Boeri,et al.  Preferences for long‐acting Pre‐Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment , 2020, Journal of the International AIDS Society.

[20]  A. van der Straten,et al.  Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study , 2020, Journal of the International AIDS Society.

[21]  J. Baeten,et al.  PrEP rollout in Africa: status and opportunity , 2020, Nature Medicine.

[22]  J. Justman,et al.  Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women , 2020, EClinicalMedicine.

[23]  S. Delany-Moretlwe,et al.  The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study , 2020, Journal of the International AIDS Society.

[24]  J. Baeten,et al.  Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. , 2019, The lancet. HIV.

[25]  A. van der Straten,et al.  Efficacy is Not Everything: Eliciting Women’s Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment , 2019, AIDS and Behavior.

[26]  B. Chi,et al.  The landscape for HIV pre-exposure prophylaxis during pregnancy and breastfeeding in Malawi and Zambia: A qualitative study , 2019, PloS one.

[27]  J. Justman,et al.  Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076) , 2019, Journal of the International AIDS Society.

[28]  L. Myer,et al.  HIV incidence during breastfeeding and mother-to-child transmission in Cape Town, South Africa. , 2019, AIDS.

[29]  D. Szydlo,et al.  Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study. , 2019, Contraception.

[30]  A. van der Straten,et al.  End‐user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study , 2019, Journal of the International AIDS Society.

[31]  Gabrielle E. O'Malley,et al.  PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial , 2019, BMJ Open.

[32]  A. van der Straten,et al.  “We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study , 2019, International journal of women's health.

[33]  L. Bekker,et al.  Global PrEP roll-out: recommendations for programmatic success. , 2019, The lancet. HIV.

[34]  A. van der Straten,et al.  Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa , 2019, Journal of acquired immune deficiency syndromes.

[35]  J. Baeten,et al.  HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Preexposure Prophylaxis During Pregnancy. , 2018, AIDS patient care and STDs.

[36]  A. van der Straten,et al.  The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention , 2018, Journal of the International AIDS Society.

[37]  Ashley J. Mayo,et al.  Acceptability and use of a dapivirine vaginal ring in a phase III trial. , 2017, AIDS.

[38]  Qingfeng Li,et al.  Contraceptive Practice in Sub-Saharan Africa. , 2017, Population and development review.

[39]  A. van der Straten,et al.  Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa , 2016, PloS one.

[40]  S. A. Abdool Karim,et al.  Trends in HIV Prevalence in Pregnant Women in Rural South Africa , 2015, Journal of acquired immune deficiency syndromes.

[41]  G. Rutherford,et al.  Mother-to-Child Transmission of HIV in Kenya: Results From a Nationally Representative Study , 2014, Journal of acquired immune deficiency syndromes.

[42]  K. Grumbach,et al.  Women's preferences for contraceptive counseling and decision making. , 2013, Contraception.

[43]  J. R. Koch,et al.  A preliminary investigation of the AUDIT and DUDIT in comparison to biomarkers for alcohol and drug use among HIV-infected clinic attendees in Cape Town, South Africa. , 2012, African journal of psychiatry.

[44]  Matt Stevenson,et al.  Alcohol Use Disorders Identification Test , 2010 .

[45]  D. Kivlahan,et al.  The AUDIT Alcohol Consumption Questions (AUDIT-C) An Effective Brief Screening Test for Problem Drinking , 2010 .

[46]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[47]  I. Kleinschmidt,et al.  Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey , 2005, AIDS.

[48]  Christine A Varga,et al.  How gender roles influence sexual and reproductive health among South African adolescents. , 2003, Studies in family planning.

[49]  D. Kivlahan,et al.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.

[50]  H. Klein,et al.  The Pre-Exposure Prophylaxis (PrEP) Stigma Scale: Preliminary findings from a pilot study. , 2019, International public health journal.

[51]  S. Delany-Moretlwe,et al.  Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa , 2018, Medical decision making : an international journal of the Society for Medical Decision Making.